FTC Docket C-3957

Pfizer Inc., and Warner-Lambert Company

Last amended: 2000Year: 2000Length: 110 wordsOfficial source
Tags: Competition Merger Horizontal Health Care Prescription Drugs Last Updated July 28, 2000 In the Matter of Pfizer Inc., and Warner-Lambert Company FTC Matter/File Number 0010059 Docket Number C-3957 Enforcement Type Part 2 Consents Case Summary Final consent order permits Pfizer’s merger with Warner-Lambert Company and requires divestitures in several pharmaceutical markets including: Pfizer’s RID brand of head lice treatment; Pfizer’s antidepressant drug, Celexa; Warner’s Cognex, a drug used in the treatment of Alzheimer’s disease; and assets relating to the Epidermal Growth Factor receptor tryosine kinase inhibitor - drugs under development to treat solid cancerous tumors such as head and neck, non-small cell lung, breast, ovarian, pancreas and colorectal cancers.
FTC Docket C-3957: Pfizer Inc., and Warner-Lambert Company | Justis AI